Are you ready for the changes ahead?

Article

Welcome to this, the glaucoma special issue of Ophthalmology Times Europe. This month we aim to give you a taste of events from the International Glaucoma Society meeting, which was held in Athens in March. If you were not able to make it, we hope this section will allow you to feel as though you did not miss out on some of the important presentations.

Elsewhere, we are also focusing heavily on practice management this month. With the advent of new therapies, equipment and knowledge, more and more patients are thankfully now treatable across a number of ophthalmic disease areas. These innovations have, naturally, led to a greater demand for skilled professionals, equipment and general resources to cope with the rising demands imposed on today's ophthalmologist.

Age-related macular degeneration (AMD) is one disease area that is currently experiencing a great deal of change. Those specialists that treat patients with AMD are all too aware that the launch of a new class of therapeutics has signified a drastic shift in their practice patterns; it is estimated that the number of patients attending a retina specialist for AMD treatment and monitoring could increase six-fold as these new treatments are made available across Europe.

The results of the expert discussion are published within the supplement to this issue. I would like to encourage you to please contact me should you wish to make any comments or raise any queries relating to the supplement or, indeed, any articles within this issue of Ophthalmology Times Europe.

Fedra PavlouEditorfpavlou@advanstar.com

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.